WZ4002 Size:10mg solid and Solubility

and Solubility

Approximately one third of patients with HCC whose tumors express FGF19 together with FGFR4 and its coreceptor klotho β (KLB) could potentially respond to treatment with an FGFR4 inhibitor

a significant increase in heart weight is observed after Dp44mT (0

InChi: InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8

WZ4002 Size:10mg solid and SolubilityWZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib. WZ4002 has a basic chemical framework (covalent pyrimidine) which is different from that of other EGFR inhibitors. This agent is 30 to 100 fold more potent against EGFR T790M, and up to 100 fold less potent against wildtype EGFR, than quinazoline based EGFR inhibitors (HKI 272 and CL